What Success Can Look Like, Darn It (opens in new tab)

I wrote here last year about the clinical trial results for the first “bifunctional degrader” molecule to make it that far, vepdegestrant from Arvinas and Pfizer. That post will send you to some background information about this class of molecule, but suffice it to say that they represent a completely new mode of action (destruction of a target protein in the living cell as opposed to chemical inhibition of it). As such, this program has been watched closely, and the results were. . .not spec...